Oncology - Upper gastrointestinal cancers
Esophageal cancer
Esophageal cancer is a malignant tumor that originates in the wall of the muscular tube connecting the pharynx to the stomach. Approximately 25 centimeters long, the esophagus passes through the neck, the chest, and the diaphragm before reaching the esophagogastric junction. It can be the site of two major histological types of cancer: squamous cell carcinoma, which develops from the squamous cells lining the upper and middle thirds of the esophagus, and adenocarcinoma, which originates in the glandular cells of the lower third, most often against a background of Barrett’s esophagus—an intestinal metaplasia induced by chronic gastroesophageal reflux. These two forms differ significantly in terms of their risk factors, epidemiology, location, and prognosis. Esophageal cancer is unfortunately characterized by late diagnosis in the majority of cases: symptoms—dominated by progressive dysphagia, i.e., increasing difficulty swallowing—often do not appear until the tumor has already obstructed a significant portion of the esophageal lumen. This late presentation explains why most esophageal cancers are diagnosed at an advanced stage, with an overall five-year survival rate that remains below 20% across all stages, but which can exceed 50% when the tumor is detected at a localized stage. In Quebec, as in the rest of Canada, the incidence of esophageal adenocarcinoma has been steadily increasing for several decades, in parallel with the rise in obesity and chronic gastroesophageal reflux in the population.
Main histological types
The distinction between the two major histological types of esophageal cancer is fundamental, as it influences risk factors, tumor location, management, and prognosis:
| Characteristic | Squamous cell carcinoma (SCC) | Adenocarcinoma (AC) |
|---|---|---|
| Cell origin | Malpighian cells (squamous epithelium) of normal esophageal mucosa | Glandular cells of intestinal metaplasia (Barrett's esophagus), transformation of squamous epithelium into intestinal columnar epithelium due to chronic acid reflux |
| Preferred localization | Upper and middle thirds of the esophagus (cervical and mid-thoracic esophagus) | Lower esophagus and esophagogastric junction |
| Key risk factors | Smoking, excessive alcohol consumption, diet low in fruits and vegetables, very hot beverages (mate), achalasia, history of cervical radiotherapy | Chronic gastroesophageal reflux disease (GERD), Barrett's esophagus, abdominal obesity, smoking, male sex, advanced age |
| Epidemiological profile | Predominant in developing countries and Central Asia; slightly decreasing in Western countries with the decline in smoking | Strong increase in Western countries since the 1970s-1980s; parallel to the obesity and GERD epidemic; mainly affects white men over 60 years old |
| Relative Prognosis | Globally grim prognosis for advanced stages; better than adenocarcinoma for early stages treated surgically | Prognosis comparable to EC for advanced stages; better response to perioperative chemotherapy in resectable stages |
ℹ️
Barrett's esophagus is a precancerous condition characterized by the replacement of the normal squamous epithelium in the lower third of the esophagus with intestinal-type columnar epithelium, in response to chronic acid exposure caused by gastroesophageal reflux. It is present in approximately 10 to 15% of patients with symptomatic chronic GERD. The risk of progression to adenocarcinoma is estimated at 0.1 to 0.3% per year, but this risk increases significantly in the presence of high-grade dysplasia. Regular endoscopic surveillance (every 3 to 5 years depending on the degree of dysplasia) is recommended for patients with confirmed Barrett’s esophagus.
Risk factors
The risk factors for esophageal cancer differ depending on the histological type, but some—notably smoking—are common to both forms:
| Risk factor | Type(s) concerned | Mechanism and risk level |
|---|---|---|
| Current or former smoker | CE and AC | Tobacco carcinogens directly damage the esophageal lining and potentiate the effect of acid reflux; the risk is multiplied by 2 to 5 depending on the duration and intensity of smoking; the risk gradually decreases after quitting but does not return to the level of non-smokers for 20 to 30 years |
| Excessive alcohol consumption | Primarily CE | Alcohol is a powerful esophageal carcinogen for EC; the risk is multiplied by 5 to 10 for heavy consumers; the combination of alcohol and tobacco is synergistic with a risk multiplied up to 40 times compared to non-smokers and non-drinkers. |
| Chronic gastroesophageal reflux | AC primarily | Untreated or inadequately controlled chronic acid reflux causes repeated inflammation of the lower third of the esophagus, inducing Barrett's metaplasia and progressively increasing the risk of adenocarcinoma; weekly symptomatic GERD doubles the risk compared to the general population |
| Abdominal obesity | AC | Abdominal obesity increases intra-abdominal pressure, promotes acid reflux and Barrett's esophagus; it is also associated with increased insulin levels and protumor growth factors; the risk of adenocarcinoma is multiplied by 2 to 4 depending on BMI. |
| Barrett's esophagus | AC | Direct precancerous lesion; the risk of progression to adenocarcinoma is 0.1 to 0.3 per 1,000 per year in the absence of dysplasia, but may exceed 6 per 1,000 per year in cases of high-grade dysplasia; warrants regular endoscopic surveillance |
| Achalasia | CE | Esophageal motor disorder leading to chronic food stasis and mucosal inflammation; the risk of EC is multiplied by 10 to 50 compared to the general population after 15 to 20 years of progression. |
| Diet low in fruits, vegetables, and antioxidants | Primarily CE | Deficiency in vitamins A, C, E, and zinc, micronutrients that protect the esophageal lining; associated with a higher incidence in populations with low fresh vegetable consumption. |
| Consumption of very hot beverages (mate, hot tea) | CE | Classified as a probable carcinogen (Group 2A) by the IARC when consumed at temperatures above 65°C; repeated thermal injury to the mucosa promotes carcinogenic mutations |
| Male sex and age | CE and AC | Men are 3 to 4 times more affected than women for adenocarcinoma and 2 to 3 times more for squamous cell carcinoma; peak incidence between 60 and 70 years of age for both forms |
Symptoms
Esophageal cancer is often asymptomatic in the very early stages. Symptoms usually appear when the tumor has reached a size sufficient to narrow the esophageal lumen or invade adjacent structures:
- Progressive dysphagia—increasing difficulty swallowing—first with solids, then with semi-liquids, and finally with liquids; this is the cardinal symptom of esophageal cancer, present in more than 80% of cases at diagnosis, but which only appears when the tumor obstructs at least 50 to 60% of the esophageal lumen
- Odynophagia — pain on swallowing — localized in the sternal or interscapular region, which may precede or accompany dysphagia
- Unintentional and significant weight loss, often severe at diagnosis due to reduced food intake related to dysphagia; a sign of poor prognosis and a marker of advanced malnutrition.
- Regurgitation of food — return of undigested food into the mouth without vomiting effort — secondary to progressive mechanical obstruction of the esophagus
- Persistent chest pain, retrosternal or dorsal, which can radiate to the back or shoulder, indicating tumor extension to mediastinal structures
- Hoarseness or dysphonia due to damage to the left recurrent laryngeal nerve, whose anatomical path runs along the esophagus in the upper mediastinum; sign of advanced local extension
- Chronic cough or recurrent pneumonia due to esotracheal or esophagobronchial fistula—abnormal communication between the esophagus and airways—a formidable complication of tumors invading the respiratory tract
- Persistent hiccups, hematemesis (vomiting blood) or melena (black stools) due to tumor bleeding; upper gastrointestinal bleeding which may be the initial presentation in some cases.
- General signs of metastatic evolution: profound fatigue, anemia, bone pain, palpable cervical lymphadenopathies (Virchow's node in the left supraclavicular fossa).
Diagnosis
Esophageal cancer diagnosis is based on a structured clinical and paraclinical evaluation, with upper gastrointestinal endoscopy with biopsies at its core.
- Medical history and clinical examination: assessment of dysphagia (onset, progression, affected foods), risk factors, weight loss, and overall nutritional status; palpation of cervical and supraclavicular lymph nodes
- Upper digestive endoscopy (gastroscopy) with multiple biopsies: this reference examination allows for direct visualization of the tumor, precise determination of its location and intraluminal extension, and the obtaining of tissue fragments for histopathological analysis to confirm the histological diagnosis and tumor type.
- Endoscopic ultrasound (esophageal ultrasound-endoscopy): high-precision locoregional staging examination for assessing the depth of esophageal wall infiltration (T stage) and involvement of periesophageal lymph nodes (N stage); fundamental surgical information
- Thoraco-abdomino-pelvic CT scan with contrast injection: assessment for distant spread, search for hepatic, pulmonary, adrenal, or bone metastases, and evaluation of anatomical relationships with mediastinal structures
- PET scan (18F-FDG positron emission tomography): detection of distant metastases not visible on CT scans, assessment of mediastinal lymph node involvement; alters the treatment strategy in 10 to 20% of cases compared to CT imaging alone
- Bronchoscopy with biopsies: indicated for tumors in the upper and middle third of the esophagus to rule out tracheobronchial invasion contraindicating surgical resection.
- Nutritional assessment and general condition evaluation (WHO/ECOG score, albumin, prealbumin): determines the indication and feasibility of intensive oncological treatments (surgery, chemotherapy)
Classification and staging
The TNM (Tumor-Node-Metastasis) classification of the International Union Against Cancer (UICC) is used to stage esophageal cancer and guide treatment decisions:
| Stadium | Description | 5-year survival (approximate) |
|---|---|---|
| Stage I (T1 N0 M0) | Tumor limited to the mucosa or submucosa, with no lymph node involvement or distant metastasis | Stage 60–80 % — a stage amenable to endoscopic or curative surgical treatment with excellent outcomes |
| Stage II (T1-3 N0-1 M0) | Tumor invading the muscularis propria or adventitia, with or without involvement of 1 to 2 regional lymph nodes, without distant metastasis | Stage 30–50 % — multimodal treatment (preoperative chemoradiotherapy followed by surgery); resection is often still possible |
| Stage III (T3-4 N1-2 M0) | Tumor invading adjacent structures (pleura, pericardium, diaphragm) or involvement of 3 to 6 regional lymph nodes, without distant metastasis | 15 to 30 % — induction chemoradiotherapy followed by surgical reevaluation; resectability varies depending on the response to treatment |
| Stage IV (any T, any N, M1) | Presence of distant metastases (liver, lungs, bones, distant lymph nodes) regardless of local tumor status | Less than 5 % — palliative care; systemic chemotherapy, immunotherapy, and/or symptomatic treatment of dysphagia (esophageal prosthesis, palliative radiation therapy) |
Treatment options
Esophageal cancer management is multidisciplinary and depends closely on the histological type, tumor stage, location, and the patient's general condition:
| Treatment | Terms | Main indications |
|---|---|---|
| Endoscopic mucosal resection (EMR) | Endoscopic ablation of a tumor limited to the mucosa or superficial submucosa, with no lymphovascular invasion | Very early stage (T1a); treatment of high-grade dysplasia on Barrett's; minimally invasive technique with esophageal preservation and excellent oncological results in eligible stages |
| Surgery (esophagectomy) | Esophagectomy with reconstruction by esophagogastrostomy (gastric pull-up) or coloplasty (colonic interposition); minimally invasive approach (laparoscopy/thoracoscopy) or open surgery depending on the center | Resectable stages I–III; preceded by neoadjuvant chemoradiotherapy for stages II and III to reduce tumor size and treat micrometastases; operative mortality of 2–5% in expert centers |
| Concomitant chemoradiotherapy (CRT) | Simultaneous combination of chemotherapy (cisplatin + 5-fluorouracil or carboplatin + paclitaxel) and external beam radiotherapy on the tumor volume and draining lymph nodes | Neoadjuvant treatment before surgery (CROSS protocol for resectable adenocarcinomas and squamous cell carcinomas); curative exclusive treatment for unresectable cervical esophageal squamous cell carcinomas or in inoperable patients |
| Palliative chemotherapy | Platinum-based doublet (cisplatin or oxaliplatin) combined with 5-FU or capecitabine, with the addition of trastuzumab if HER2 is overexpressed for adenocarcinomas | Unresectable metastatic or locally advanced cancers; aims to prolong survival and control symptoms; median survival of 10 to 14 months in the first-line setting |
| Immunotherapy (checkpoint inhibitors) | Nivolumab (anti-PD-1) in combination with chemotherapy in the first-line metastatic setting; pembrolizumab according to tumor PD-L1 status | Unresectable metastatic or recurrent esophageal cancer, in the first or second line based on tumor biomolecular test results (PD-L1, MSI status); significantly improves overall survival compared to chemotherapy alone |
| Palliative treatment of dysphagia | Placement of a self-expandable metallic esophageal prosthesis (stent) via endoscopic route, palliative decongestive radiotherapy, endoscopic dilation, feeding gastrostomy or jejunostomy | Unresectable metastatic or locally advanced cancers with disabling dysphagia; objective: restore food transit to improve quality of life and maintain nutritional status |
| Nutritional support | Enteral nutrition via nasogastric tube or percutaneous endoscopic gastrostomy (PEG), high-protein oral nutritional supplements | Systematic from diagnosis in case of malnutrition; essential before and during heavy treatments to maintain general condition and reduce operative morbidity and treatment toxicity |
ℹ️
The CROSS protocol (ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study) has become the standard of care for resectable stage II and III esophageal cancers. It combines preoperative chemoradiotherapy (carboplatin + paclitaxel + 41.4 Gy of radiation therapy) followed by esophagectomy, and has demonstrated a significant improvement in overall survival compared to surgery alone, with a complete pathological remission rate of approximately 30% for adenocarcinomas and 49% for squamous cell carcinomas.
Complications and sequelae of treatment
Esophageal cancer treatment, particularly surgery and chemoradiotherapy, can lead to significant complications and functional sequelae that you should be aware of:
- Anastomotic fistula following esophagectomy—a communication between the esophagogastric anastomosis and the surrounding spaces—is the most feared surgical complication, occurring in 10 to 20% of cases depending on the series, and sometimes requiring reoperation or radiological drainage
- Aspiration pneumonia and postoperative respiratory complications, favored by partial diaphragm paralysis and stomach herniation into the chest.
- Dumping syndrome—accelerated gastric emptying leading to discomfort, sweating, and diarrhea after meals—secondary to pyloroplasty performed during gastric reconstruction
- Severe gastroesophageal reflux after esophagectomy due to absence of the lower esophageal sphincter; requires strict dietary and lifestyle measures (small, frequent meals, semi-upright position, avoidance of acidic foods).
- Late anastomotic stenosis requiring repeated endoscopic dilations to maintain satisfactory food transit
- Toxicities of chemoradiotherapy: painful acute radiation esophagitis, myelosuppression, platinum-induced peripheral neuropathy, nausea, and persistent fatigue
- Chronic malnutrition and nutritional deficiencies (vitamin B12, iron, calcium, fat-soluble vitamins) requiring supplementation and specialized long-term dietary monitoring.
Prevention and screening
In the absence of a systematic screening program for the general population in Quebec, primary prevention and surveillance of at-risk groups are the main strategies to reduce mortality related to esophageal cancer:
- Smoking cessation: most effective primary prevention measure for both histological types; the risk gradually decreases after cessation but remains higher than in non-smokers for 20 to 30 years
- Reduction of alcohol consumption, particularly in combination with tobacco, whose carcinogenic effect on the esophageal mucosa is strongly synergistic
- Active management of chronic gastroesophageal reflux disease with dietary and lifestyle modifications, proton pump inhibitors, and regular monitoring in persistently symptomatic patients
- Body weight control and treatment of abdominal obesity, an independent risk factor for esophageal adenocarcinoma
- Regular endoscopic surveillance of patients with confirmed Barrett's esophagus, according to gastroenterology society recommendations (intervals varying from 3 to 5 years depending on the presence and degree of dysplasia)
- Preemptive treatment of high-grade dysplasia on Barrett's esophagus by radiofrequency ablation (RFA) or endoscopic resection, before transformation into invasive adenocarcinoma
- Diet rich in fresh fruits and vegetables, providing antioxidants (vitamins C, E, beta-carotene) that protect the esophageal lining
- Avoid consuming very hot beverages (mate, tea) at temperatures above 65°C (149°F), classified as probable carcinogens by the IARC.
Signs requiring immediate medical attention
Any progressive dysphagia—increasing difficulty swallowing solids, then semi-liquids—appearing in an adult over 50 years of age, with or without unintentional weight loss, must be evaluated without delay by a physician. This symptom is a major alarm sign that requires an emergency diagnostic gastroscopy to rule out esophageal cancer or another severe organic pathology of the upper gastrointestinal tract. Persistent odynophagia, unexplained chest pain, food regurgitation, and recent-onset hoarseness are other alarm signs that warrant prompt consultation, particularly in patients with risk factors (smoking, alcohol consumption, chronic GERD, history of Barrett's esophagus).
In the presence of upper gastrointestinal bleeding (vomiting blood or black stools), complete difficulty swallowing liquids, or respiratory distress associated with swallowing difficulties, call 911 immediately or go to the nearest emergency room. For any persistent dysphagia or upper digestive symptoms without signs of immediate emergency, a consultation at Clinique Omicron allows for a rapid medical evaluation and referral to appropriate gastroenterology or oncology resources.
Consult at Clinique Omicron
Clinique Omicron provides initial assessment of upper digestive symptoms, prescription of biological assessments, and referral to specialized gastroenterology and digestive oncology resources at its various service points in Quebec and via telemedicine. A physician or nurse practitioner (NP) can assess your symptoms, prescribe appropriate investigations, and coordinate an urgent referral to a gastroenterologist for gastroscopy if a red flag is identified. To book an appointment at one of our service points or via telemedicine, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for the advice of a qualified healthcare professional. Consult a doctor for any persistent digestive symptoms, abnormal results, or decisions regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.